TRUE Private Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

TRUE Private Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-400	Closed	-$5K	–	715
2020 Q2	$5K	Hold	400	–	–	﹤0.01%	559
2020 Q1	$4K	Buy	+400	New	+$7.52K	﹤0.01%	542

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TRUE Private Wealth Advisors's HRTX Position: Q3 2020 in Review

TRUE Private Wealth Advisors sold out of Heron Therapeutics (HRTX) in Q3 2020, closing a stake of 400 shares — an estimated $5K sold.

TRUE Private Wealth Advisors first reported a position in HRTX in Q1 2020 and held it in 2 quarters. The position peaked at $5K in Q2 2020. 182 funds tracked by Wall St. Rank hold HRTX as of Q3 2020.

TRUE Private Wealth Advisors reported no remaining Heron Therapeutics position as of Q3 2020 after selling out during the quarter.
TRUE Private Wealth Advisors sold 400 Heron Therapeutics shares in Q3 2020, an estimated $5K.
TRUE Private Wealth Advisors first reported a position in Heron Therapeutics in Q1 2020 and held it in 2 quarters.
TRUE Private Wealth Advisors's Heron Therapeutics position peaked at $5K in Q2 2020.
182 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2020.

Based on TRUE Private Wealth Advisors's 13F filing for Q3 2020, filed 9 Oct 2020.